TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06609642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art application
Description: First, participants will complete questionnaires that will provide us with their socio-demographic information, their level of knowledge in visual arts and music, as well as their level of eco-anxiety.~Second, participants will use the application on a touchscreen tablet:~1. A member of the research team will give a brief explanation of the application.~2. The participant will use the application on the touchscreen tablet.~3. A member of the research team will be present in the room during the test as an observer.~Third, the participant will answer questions from a member of the research team: impressions of the tool, digital skills and abilities, enablers and barriers to the use of the tool, expectations, needs, and interests in the application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art application
Description: First, participants will complete questionnaires that will provide us with their socio-demographic information, their level of knowledge in visual arts and music, as well as their level of eco-anxiety.~Second, participants will use the application on a touchscreen tablet:~1. A member of the research team will give a brief explanation of the application.~2. The participant will use the application on the touchscreen tablet.~3. A member of the research team will be present in the room during the test as an observer.~Third, the participant will answer questions from a member of the research team: impressions of the tool, digital skills and abilities, enablers and barriers to the use of the tool, expectations, needs, and interests in the application.
Study: NCT06612710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extracellular vesicles derived from human induced neural stem cell for intravenous injection
Description: extracellular vesicles derived from human induced neural stem cell for intravenous injection（4×10\^9 particles/kg）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection
Description: extracellular vesicles placebo (4×10\^9 particles/kg)
Study: NCT06613256

Intervention type: OTHER
Intervention: Endothelial cell biopsy
Description: Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis

Intervention type: OTHER
Intervention: Endothelial cell biopsy
Description: Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis

Intervention type: OTHER
Intervention: Endothelial cell biopsy
Description: Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
Study: NCT04777110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
Study: NCT06613256

Intervention type: OTHER
Intervention: Endothelial cell biopsy
Description: Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis

Intervention type: OTHER
Intervention: Endothelial cell biopsy
Description: Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
Study: NCT06612788

Intervention type: DEVICE
Group type: OTHER
Intervention: Exablate Model 4000 Type 2.0/2.1
Description: There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
Study: NCT04777110

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s
Study: NCT05262452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system
Description: Device to deliver mechanical stress and force to enhance drug delivery, using focused ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX regimen
Description: a chemotherapy regimen for treatment of advanced pancreatic cancer~* FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU~* F : 5-FU, a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis~* IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.~* OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis
Study: NCT05070364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a
Description: Immunomodulator
Study: NCT05072210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Intervention
Description: Active mobile data will be used to provide automated, personalized notifications to frontline healthcare workers. Key information on mental health and links to access additional health resources will be available on the mobile platform.
Study: NCT06486051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day IV for three consecutive days
Study: NCT05312281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device : Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo
Description: Wear for 6 weeks post-surgery
Study: NCT06486051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2/day IV for three consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WZTL-002 CAR T-cells
Description: WZTL-002 comprises autologous T-cells transduced to express the third-generation 1928T2z chimeric antigen receptor, which recognises the CD19 antigen present on malignant and normal B-cells. The chimeric antigen receptor (CAR) incorporates an extracellular scFv specific for CD19, the intracellular signalling domains of CD28 and CD3ζ, and an intracellular co-stimulatory domain derived from TLR2 interposed between CD28 and CD3ζ.~On Day 0, the WZTL-002 CAR T-cell product is administered intravenously two days after completing lymphodepleting chemotherapy.
Study: NCT04536675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol and Umeclidinium Bromide
Description: Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
Study: NCT05803759

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Allicor
Description: Each capsule contains 150 mg dried garlic powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules manufactured to mimic Allicor 150 mg capsules
Study: NCT05008445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM-102 Injection
Description: LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM-102 Injection
Description: LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM-102 Injection
Description: LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM-102 Injection
Description: LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM-102 Injection
Description: LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LM-102 Injection combined with SOC
Description: LM-102 Injection with appropriate dose level(s), combined with SOC.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LM-102 Injection combined with SOC
Description: LM-102 Injection with appropriate dose level(s), combined with SOC.
Study: NCT04571216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFL-101 dose 1
Description: Subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFL-101 dose 2
Description: Subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections
Study: NCT04723589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thawed plasma
Description: Plasma not labeled convalescent plasma is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study.
Study: NCT05365919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention
Description: FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
Study: NCT06061237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Thai dance exercise
Description: Aerobic Thai dance exercise 60 minute per times, 3 times per weeks of 12 weeks. Aerobic exercise of modulate intensity (12-13 Borg's RPE)
Study: NCT05656911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabedosertib (BAY1834845)
Description: Oral administration, two times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to zabedosertib (BAY 1834845)
Description: Oral administration, two times a day
Study: NCT05089045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study: NCT05420545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT06037837

Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgeons will perform and participants will undergo robotic surgery according to the standard of care. No additional interventions will be performed on participating participants.
Study: NCT05988723

Intervention type: OTHER
Intervention: ELISA kits
Description: Making biochemical measurements with the ELISA kit

Intervention type: OTHER
Intervention: ELISA kits
Description: Making biochemical measurements with the ELISA kit
Study: NCT06016218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
Study: NCT05427227

Intervention type: DEVICE
Intervention: EV-array detection
Description: Collect peripheral blood sample of 500 GI patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect certain exosome proteins expression by EV-array.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.

Intervention type: DEVICE
Intervention: EV-array detection
Description: Collect peripheral blood sample of 500 GI patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect certain exosome proteins expression by EV-array.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.

Intervention type: DEVICE
Intervention: EV-array detection
Description: Collect peripheral blood sample of 500 GI patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect certain exosome proteins expression by EV-array.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study: NCT05584358

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry protein blend ingestion
Description: Ingestion of protein blend powders mixed in water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extruded protein blend ingestion
Description: Ingestion of protein blend powders mixed in water
Study: NCT04982770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Reading of ethical guidelines.
Study: NCT05422053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 insulin pump with Control-IQ technology 1.5
Description: t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.
Study: NCT04906681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-ACT
Description: i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-ACT
Description: i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.
Study: NCT05576376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: calcaneal osteotomy for intractable plantar fasciitis
Description: plantar displacement calcaneal osteotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plantar fascia open release
Description: open partial release with or without baxter's nerve decompression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plantar fascia endoscopic release
Description: endoscopic partial plantar fascia release
Study: NCT05756296

Intervention type: PROCEDURE
Intervention: Therapeutic hypothermia
Description: whole-body cooling to an esophageal temperature of 33.5°C initiated within the first 6 hours of life, continued for 72 hours, and then they were slowly rewarmed for moderate or severe NE
Study: NCT05929989

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA TEST
Description: ELISA TEST for cystatin D and fibrinogen like protein

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA TEST
Description: ELISA TEST for cystatin D and fibrinogen like protein
Study: NCT04813107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APL-1202 in combination with tislelizumab
Description: For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tislelizumab alone
Description: For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
Study: NCT05461352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 5 mg
Description: Participants received repeated doses of 5 mg of TS-142 (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 10 mg
Description: Participants received repeated doses of 10 mg of TS-142 (oral tablet)
Study: NCT05978700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-game
Description: The video-game has three games: (1) Game One - Lip Exercise; (2) Game Two - Tongue Exercises; (3) Game Three - Lower Jaw Exercise. The whole training will take about once a day for 30 min per session, 5 times a week for 4 weeks.
Study: NCT05299255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: the placebo as control group.
Study: NCT05423899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grace Robot
Description: The Grace robot was designed by Awakening Health/Hanson Robotics for healthcare settings and to interact with the elderly and those isolated by the COVID-19 pandemic. Grace is a robot with a human-like appearance, which can move, actively listen, engage in conversation and react appropriately to human emotions. Intervention activities will mostly consist of active listening and general discussions about topics of interest (e.g. hobbies, music). The participant will also have the option of other types of interactions with the robot, including robot-led meditation, robot-led light exercise, listening to music and singing. Because loneliness is a subjective experience and does not have a standardized solution, this is a personalized intervention approach. We anticipate that each older adult participant will have different needs and wishes when interacting with the robot, which will allow for a more natural interaction with the robot.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The treatment as usual active control group will not receive the robot intervention. The investIgators have deliberately chosen the participating long-term care (LTC) homes due to their high frequency of social interactions for their clients as part of their routine care (e.g. one-on-one and group activities, family interaction, exercise groups) compared to most LTC homes settings, making TAU an active control.
Study: NCT06241781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT101 injection
Description: GT101 injection to treat cervical cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine injection
Description: Gemcitabine injection to treat cervical cancer
Study: NCT04238013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration (WBV)
Description: The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration (WBV)
Description: The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.
Study: NCT05424146

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic Bar +CPT
Description: Participants will be instructed to consume 1 prebiotic bar once daily for 1 week CPT. Starting week 2 they will be asked to consume 1 prebiotic bar twice daily.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Prebiotic Bar +CPT
Description: Participants will be instructed to consume 1 non-prebiotic bar once daily for 1 week while receiving CPT. Starting week 2 they will be asked to consume 1 non-prebiotic bar twice daily.